Alex Gorsky Archives - CFO

J&J Gets Boost From Strong Cancer Drug Sales

Financial Performance

J&J Gets Boost From Strong Cancer Drug Sales

The company's Q3 earnings beat estimates but "it remains too early to call for a broad recovery" in the medical-device and consumer businesses.

By Matthew Heller | October 16, 2018

J&J’s Dominic Caruso to Step Down as CFO

J&J’s Dominic Caruso to Step Down as CFO

The company's longest-serving finance chief, who presided over three of its largest acquisitions, will be replaced by investor relations VP Joseph Wolk.

By Matthew Heller | March 21, 2018

J&J, Aetna CEOs Hit Fee-for-Service System

Human Capital & Careers

J&J, Aetna CEOs Hit Fee-for-Service System

The chief executives of two health-care giants want the industry to move further toward payments based on quality of care.

By David Katz | November 14, 2017

J&J Posts $17.7B in Revenue, Misses Estimates

Financial Performance

J&J Posts $17.7B in Revenue, Misses Estimates

Tepid growth in pharmaceuticals and consumer products held back first-quarter sales but the company is still confident it will meet its full-year guidance.

By Matthew Heller | April 19, 2017

J&J Boosts Drug Roster With $30B Actelion Deal

J&J Boosts Drug Roster With $30B Actelion Deal

The largest acquisition in J&J's history gives it access to Actelion's portfolio of high-margin treatments for rare diseases.

By Matthew Heller | January 26, 2017

J&J Sales Increase 1.7% But Miss Estimates

J&J Sales Increase 1.7% But Miss Estimates

Earnings jumped 19% to $3.81 billion in the fourth quarter, but sales were hit by slowing demand for medical devices.

By Matthew Heller | January 24, 2017